Introduction {#s1}
============

A leading cause of blindness worldwide, glaucoma is a devastating disease with no cure. Elevated intraocular pressure (IOP) caused by defects in the aqueous humor outflow (AHO) pathway is the most important risk factor for disease progression and vision loss ([@bib10]; [@bib4]). Indeed, IOP reduction is currently the only therapeutic intervention proven to slow glaucoma progression in patients. In both humans and mice, the majority of AHO occurs through the conventional route ([@bib16]; [@bib39]; [@bib40]; [@bib24]; [@bib25]), comprised of the trabecular meshwork (TM) and the large, lymphatic-like Schlemm's canal (SC) located in the iridocorneal angle ([@bib16]; [@bib27]; [@bib2]; [@bib21]). Aqueous humor from the anterior chamber enters SC through the TM and is drained through a series of collector channels into the episcleral veins and systemic circulation. Recent studies have identified the importance of endothelial signaling molecules in development and maintenance of SC and the conventional outflow pathway, and critical roles have been described for the endothelial transcription factor PROX1 ([@bib27]) as well as the VEGFR2/3 ([@bib21]; [@bib2]) and TEK ([@bib36]; [@bib20]; [@bib33]; [@bib37]) receptor tyrosine kinase signaling pathways.

TEK (Tunica interna endothelial cell kinase, also known as TIE2) is the tyrosine kinase receptor for the angiopoietin (Angpt) ligands ANGPT1, ANGPT2 and ANGPT4 ([@bib30]). The Angpt-TEK pathway is essential for SC development and maintenance, and loss of function mutations in *TEK *or the gene encoding its primary ligand *ANGPT1* have been identified in patients with primary congenital glaucoma, a severe form of glaucoma characterized by early/childhood onset, buphthalmos and optic neuropathy ([@bib33]; [@bib37]; [@bib17]). Furthermore, recent genome-wide association studies have identified risk variants linked to the TEK signaling pathway in adults with elevated IOP and open angle glaucoma, the most common form of glaucoma worldwide ([@bib18]; [@bib13]; [@bib22]).

In mice, post-natal *Tek* deletion leads to complete failure of SC development and rapidly progressing glaucoma ([@bib36]; [@bib20]; [@bib33]). A similar disease is observed in mice lacking the TEK ligand ANGPT1, confirming that ANGPT-TEK signaling is essential for canal development ([@bib37]). Importantly, while *Tek* knockout mice exhibit complete loss of SC, a hypomorphic canal characterized by focal narrowing and convolutions is observed in haploinsufficient animals (*Tek*^+/-^ mice) ([@bib33]). This hypomorphic SC is associated with moderate IOP elevation, indicating a clear dose-dependent effect of TEK signaling in development and function of the aqueous outflow pathway and suggesting that TEK activation using genetic or pharmacological approaches might provide novel treatments for patients with high-pressure glaucoma. Indeed, the clear dose-dependent relationship between ANGPT-TEK signaling and severity of disease presentation in rodent models supports the argument that therapeutic modulation of this pathway will be efficacious in patients ([@bib29]).

Activation of the TEK receptor has been achieved in vitro and in vivo either by increasing activity of endogenous ANGPT ligands, providing ANGPT recombinant proteins ([@bib19]; [@bib34]), or by suppression of the phosphatase PTPRB (also known as the Vascular Endothelial Protein Tyrosine Phosphatase, VE-PTP) ([@bib42]; [@bib32]; [@bib9]), which strongly dephosphorylates TEK ([@bib34]; [@bib12]). PTPRB inhibition results in ligand-independent increased TEK phosphorylation at all phosphorylated tyrosine residues, and leads to a dramatic increase in downstream signaling ([@bib34]; [@bib9]). Here, we show that developmental deletion of a single *Ptprb* allele in mice is sufficient to reduce PTPRB expression and leads to increased TEK activation in vivo. Furthermore, in *Tek*^+/-^ haploinsufficient mice, this increased TEK activation is sufficient for normal SC development, preventing both ocular hypertension and retinal ganglion cell (RGC) loss.

Results {#s2}
=======

To increase the level of TEK phosphorylation in vivo, we utilized a *Ptprb*^NLS-LacZ^ knock-in reporter allele ([@bib3]) to delete a single allele of the *Ptprb* gene. This construct incorporates a β-Galactosidase cDNA tagged with a nuclear localization signal in place of the first exon of *Ptprb*, preventing production of PTPRB protein. As previously described, heterozygous *Ptprb*^NLS-LacZ/WT^ mice are born normally ([@bib3]), although expression of PTPRB was reduced by approximately 50% ([Figure 1A](#fig1){ref-type="fig"}, uncropped images presented as [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Likewise, *Tek* heterozygosity resulted in approximately 50% reduction in TEK protein detected in lung lysate ([Figure 1A](#fig1){ref-type="fig"}). Reductions in phosphatase abundance had a direct effect on TEK activation and *Ptprb*^NLS-LacZ/WT^ mice showed approximately a 118% increase in phosphorylated TEK when measured in lung tissue using an immunoprecipitation assay ([Figure 1B](#fig1){ref-type="fig"}, uncropped images presented as [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), confirming our hypothesis that changes in PTPRB expression would have a direct impact on TEK phosphorylation.

![Deletion of one *Ptprb* allele leads to increased TEK phosphorylation.\
(**A**) Western blot of lung lysate from P5 Control, *Tek*^+/-^, *Ptprb*^NLS-LacZ/WT^ and *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice revealed a 50% reduction in PTPRB expression in *Ptprb*^NLS-LacZ/WT^ (heterozygous) and *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice. Likewise, TEK expression was reduced approximately 50% in *Tek*^+/-^ and *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice. (**B**) Immunoprecipitation of lung lysates from adult control and *Ptprb*^NLS-LacZ/WT^ using anti-TEK antibody followed by western blotting with anti-phospho tyrosine antibody revealed a marked elevation of TEK phosphorylation in *Ptprb*^NLS-LacZ/WT^ animals compared to littermate controls. Horizontal lines indicate population means. \*p\<0.05, \*\*\*p\<0.001 as determined by Student's t-test.](elife-48474-fig1){#fig1}

The finding that *Ptprb*^NLS-LacZ/WT^ haploinsufficient mice exhibited markedly increased TEK phosphorylation suggested that these animals would provide a powerful tool to study the effect of PTPRB blockade on SC development in the context of reduced TEK signaling. Therefore, we crossed mice carrying the *Ptprb*^NLS-LacZ^ allele with a previously-described mouse model of *Tek* heterozygosity, creating a constitutive model of *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ double haploinsufficency. Adult *Tek* haploinsufficient mice have been reported to exhibit a hypomorphic SC insufficient for normal AHO, leading to moderate IOP elevation ([@bib33]). To test our hypothesis that \~50% reduction of PTPRB activity might prevent the glaucoma phenotype in *Tek^+/-^* mice without the need to increase ligand availability, *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ double heterozygous mice were generated, and enucleated eyes were collected. After fixation, eyes were prepared for whole-mount immunostaining and visualized using confocal microscopy. Consistent with previous findings ([@bib33]), analysis of CD31-positive SC area revealed a hypomorphic canal phenotype in adult *Tek* heterozygous mice when compared to littermate controls (Control: 29,974 ± 2145, *Tek*^+/-^: 17,457 ± 1040 μm^2^/20x field; [Figure 2A](#fig2){ref-type="fig"}). This phenotype was abrogated by deletion of a single *Ptprb* allele in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ animals, which exhibited normal SC area (*Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^: 23,848 ± 1574 μm^2^/20x field). Importantly, despite elevated TEK activation, *Ptprb*^NLS-LacZ/WT^ animals displayed a normal SC (*Ptprb*^NLS-LacZ/WT^: 28,175 ± 1668 μm^2^/20x field), suggesting reduction of PTPRB function is well tolerated during SC development in the absence of other mutations.

![TEK signaling has a dose-dependent effect on Schlemm's canal (SC) area and development.\
(**A**) Confocal microscopy of whole mount eyes revealed reduced CD31+ SC area in adult *Tek*^+/-^ haploinsufficient mice. This phenotype was blunted in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ double heterozygous animals, confirming the importance of TEK activation in canal development. *Ptprb*^NLS-LacZ/WT^ heterozygous controls had normal SC area (n = 8 WT, 12 *Ptprb*^NLS-LacZ/WT^, 11 *Tek*^+/-^ and 11 *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice). 20x fields shown represent an area of 65,536 μm^2^. Images were captured as 10-frame Z stacks with a step size of 1.67 μm and a pinhole of 1.2 Airy units, and are shown as maximum intensity projections. (**B**, quantified in **C**) At postnatal day 5 (P5), confocal microscopy of the developing SC in eye whole mounts revealed reduced numbers of proliferating Ki-67-positive SC ECs (Ki67-PROX1 double positive cells) in *Tek* haploinsufficient animals compared to littermate WT or *Ptprb*^NLS-LacZ/WT^ controls. Normal proliferation was observed in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ animals. (**D**) Compared to control and *Ptprb*^NLS-LacZ/WT^ mice, PROX1 expression was reduced in *Tek*^+/-^ littermate eyes. Expression was normal in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ double heterozygotes. n = 8 (WT), 4 (*Ptprb*^NLS-LacZ/WT^), 8 (*Tek*^+/-^) and 5 (*Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^) Shown are maximum intensity projections from 8-frame confocal Z stacks captured using a 20x objective, step size of 1 μm and pinhole of 1.2 Airy units. Norm. AFU: Normalized, background subtracted arbitrary fluorescence units. (**E**) Compared to control and *Ptprb*^NLS-LacZ/WT^ littermates, confocal analysis of adult SC revealed a marked increase in the number of focal convolutions and narrowings in the eyes of *Tek*^+/-^ and *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice. N = 4 (WT), 7 (*Ptprb*^NLS-LacZ/WT^), 5 (*Tek*^+/-^) and 6 (*Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^). Horizontal lines indicate population means. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 as determined by 1-way ANOVA followed by Bonferroni's correction.](elife-48474-fig2){#fig2}

Developmental haploinsufficency of *Tek* and *Ptprb* had clear effects on adult SC area in our model. To determine if this phenotype was due to altered proliferation of SC endothelial cells (ECs), we next analyzed eyes collected at P5 when SC development is underway. In *Tek*^+/-^ eyes, we observed a marked reduction in the proportion of PROX1+ SC ECs which were also positive for Ki-67 (Control: 0.302 ± 0.022, *Tek*^+/-^: 0.214 ± 0.016), suggesting that the hypomorphic canal phenotype in these animals may be due to reduced proliferation during canal development ([Figure 2B](#fig2){ref-type="fig"}, quantified in **C**). Strikingly, normal proliferation of PROX1+ SC cells was observed in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice (*Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^: 0.345 ± 0.039), providing a potential mechanism for the observed effects on canal area in adulthood. A similar effect was observed on PROX1 expression, which was dramatically decreased in the SC of *Tek*^+/-^ eyes at P5 and appeared normal in the eyes of *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ littermates (Norm. AFU: Control: 1.0 ± 0.12, *Tek*^+/-^: 0.49 ± 0.07, *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^: 0.82 ± 0.065, [Figure 2D](#fig2){ref-type="fig"}).

In addition to decreased area, *Tek*^+/-^ SCs are characterized by focal thinning and convolutions which are not present in WT littermates ([@bib33]) ([Figure 2E](#fig2){ref-type="fig"}). Interestingly, although *Ptprb* haploinsufficency resulted in increased proliferation and expanded canal area in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ animals, these focal defects were still observed---suggesting that directional signaling may play a role in proper canal formation which cannot be recapitulated by nonspecific TEK activation.

We next examined the effect of altered SC area in *Tek*^+/-^ and *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice on aqueous humor homeostasis. *Tek* heterozygous mice on an outbred background were found to have elevated IOP at 30 weeks of age ([Figure 3A](#fig3){ref-type="fig"}, Control: 13.7 ± 0.23, *Tek*^+/-^ 18.15±0.33 mmHg). Consistent with observations of SC morphology, while *Ptprb*^NLS-LacZ/WT^ mice had normal IOP (13.81 ± 0.82 mmHg), incorporation of this allele into the *Tek*^+/-^ model was beneficial and blunted the ocular hypertension associated with *Tek* haploinsufficiency, despite the presence of focal morphological defects (*Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ IOP: 14.92 ± 0.31 mmHg). To confirm the impact of the *Ptprb*^NLS-LacZ^-induced IOP reduction on the retina, we counted BRN3B positive ganglion cells in an additional cohort of mice at 19 weeks of age ([Figure 3B](#fig3){ref-type="fig"}). While *Tek* heterozygous mice showed a marked reduction in RGCs, this loss did not occur in *Tek*^+/^;*Ptprb*^NLS-LacZ/WT^ mice.

![*Ptprb* heterozygosity prevents ocular hypertension and RGC loss in *Tek* haploinsufficient mice.\
(**A**) Elevated intraocular pressure (IOP) was observed in *Tek*^+/-^ haploinsufficient mice at 30 weeks of age when measured by rebound tonography. As in [Figure 2](#fig2){ref-type="fig"}, this phenotype was prevented in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ double heterozygous animals, confirming the importance of TEK activation in IOP homeostasis (n = 6 WT, 14 *Ptprb*^NLS-LacZ/WT^, 12 *Tek*^+/-^ and 14 *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice). (**B**) BRN3B staining in retinal flat-mounts from a second group of mice revealed loss of retinal ganglion cells by 19 weeks in *Tek*^+/-^ mice. Littermate *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ animals were protected, correlating with the reduced IOP observed (n = 4 WT, 4 *Ptprb*^NLS-LacZ/WT^, 3 *Tek*^+/-^ and 4 *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice). Horizontal lines indicate population means. \*p\<0.05, \*\*\*p\<0.001 as determined by 1-way ANOVA followed by Bonferroni's correction.](elife-48474-fig3){#fig3}

TEK signaling is critical for retinal angiogenesis, and to exclude the possibility that vascular defects and subsequent ischemia were responsible for RGC loss in *Tek*^+/-^ mice, we examined vascular morphology in our animals. We first examined retinas collected at P5, when development of the superficial vasculature is ongoing. At this timepoint, CD31 staining revealed normal progress of the angiogenic sprouting front in *Tek*^+/-^, *Ptprb*^NLS-LacZ/WT^, and *Tek*^+/^;*Ptprb*^NLS-LacZ/WT^ mice when compared to littermate controls ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). At P20, when development of the mature retinal vasculature is complete, we observed normal patterning in all three retinal vascular layers in mice of all genotypes ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). By this timepoint, hyaloid vessels were not observed in animals of any genotype. Taken together, these data suggest that blunted IOP elevation in *Tek*^+/^;*Ptprb*^NLS-LacZ/WT^ animals likely had a direct impact on glaucoma pathogenesis in our model and that retinal ischemia is unlikely to account for the RGC loss observed in Tek haploinsufficient mice.

Discussion {#s3}
==========

Ocular hypertension is the single most important risk factor for glaucoma in patients, and reducing IOP is the only therapeutic intervention proven to slow disease progression. Although aqueous humor flow through the conventional (trabecular) outflow pathway represents the majority of AHO, drugs targeting this outflow pathway were not available until the recent introduction of the Rho kinase inhibitors ripasudil and netarsudil. However, while these molecules provide exciting new treatment options, clinical trials have not shown them to be superior to current standard of care therapies for lowering IOP ([@bib35]), underscoring the need for additional drug targets and treatment options.

Angpt-TEK signaling is essential for development ([@bib36]; [@bib33]; [@bib37]) and maintenance ([@bib20]) of SC, an essential component of the conventional AHO pathway. Dysregulation of Angpt-TEK signaling results in hypomorphic or failed SC formation, elevated IOP and glaucoma in mice and humans. Intriguingly, recent GWAS studies of subjects with ocular hypertension have identified common variants in members of the Angpt-TEK signaling pathway ([@bib18]; [@bib13]; [@bib22]). These GWAS findings suggest that in addition to the complete loss-of-function variants previously described in PCG, less impactful variants may play a role in more common forms of adult-onset glaucoma. These reports, combined with the strong dose dependent response of SC development and function to TEK signaling observed in the mouse, suggest that the Angpt-TEK signaling axis is a sensitive and important regulator of SC and AHO and may provide a valuable IOP-lowering therapeutic target for treatment of glaucoma patients. Indeed, a recent study has demonstrated the effectiveness of targeting the Angpt-TEK signaling pathway in a mouse model of glaucoma using an antibody which increases the signaling ability of the context-dependent, weak TEK agonist ANGPT2 by clustering it into higher-order multimers ([@bib20]; [@bib28]). ANGPT2-clustering antibody treatment was found to increase TEK phosphorylation in aged mice and lower IOP in an injury-induced model of ocular hypertension ([@bib20]).

Here, we demonstrate an alternative approach targeting the endothelial phosphatase PTPRB, which acts on TEK ([@bib34]; [@bib42]; [@bib3]) as well as VE-Cadherin, VEGFR2 and FGD5 ([@bib26]; [@bib7]; [@bib23]; [@bib14]; [@bib6]). Using a genetic approach to PTPRB ablation allowed us to achieve consistent reduction in protein levels, with deletion of a single *Ptprb* allele leading to approximately 50% reduction in protein expression. In *Tek*-WT lung tissue, this was sufficient to cause a marked elevation in TEK phosphorylation. PTPRB inhibition has been previously studied as a potential therapeutic intervention in vascular disease ([@bib32]), and the PTPRB inhibitor AKB-9778 is currently undergoing clinical trials for treatment of diabetic macular edema, where it is well-tolerated by patients ([@bib8]). While mid-term results for the AKB-9778 TIME-2 trial failed to achieve the primary endpoint in diabetic macular edema, two important observations were reported from this clinical trial: the drug was well tolerated and safe in patients and IOP was lower in the treatment arm ([@bib1]).

We have previously reported that defects in Angpt-TEK signaling cause a range of SC and IOP phenotypes corresponding to the degree of pathway dysfunction, ranging from complete absence of SC (*Tek* knockout or *Angpt1;Angpt2* double knockout mice) to less severely hypomorphic canal morphology (*Tek* haploinsufficency) ([@bib36]; [@bib20]; [@bib33]; [@bib37]). Although the phenotype of *Tek* haploinsufficient mice is milder than that observed in PCG patients with heterozygous *TEK* loss-of-function mutations ([@bib33]), we selected this model as *Tek* heterozygous mice are viable, fertile and exhibit a consistent SC phenotype without the need for Cre recombinase-mediated gene deletion. Furthermore, this mouse model has many features of glaucoma including ocular hypertension and loss of retinal ganglion cells which more faithfully recapitulate disease seen in patients with common forms of open angle glaucoma then the more severe model of total *Tek* deletion. Consistent with our previous findings, adult *Tek*^+/-^ mice in this study displayed a hypomorphic SC phenotype due to decreased EC proliferation which was associated with elevated IOP and loss of BRN3B+ retinal ganglion cells. These defects were blunted by developmental *Ptprb* haploinsufficency in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice, likely due to increased basal TEK phosphorylation and resulting EC proliferation in *Ptprb*^NLS-LacZ/WT^ animals. In addition, expression of PROX1, a key marker of mature SC endothelial cells, was dramatically reduced in *Tek*^+/-^ SCs at P5. Expression was normal in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ eyes, consistent with previous reports from our lab and elsewhere suggesting that Angpt1-TEK signaling may be critical for maintenance of this crucial transcription factor in the SC endothelium ([@bib27]; [@bib20]; [@bib37]; [@bib41]). However, our data do not indicate whether PROX1 expression is directly downstream of TEK activation or is otherwise dependent on a mature SC endothelial phenotype.

While these results highlight the potential of PTPRB as a therapeutic target for patients with TEK-associated PCG, the recent association of Angpt-TEK variants with ocular hypertension and the findings of Kim et al using an ANGPT2 clustering antibody suggest that this pathway may also provide a valuable therapeutic target for adult patients with primary open angle glaucoma, a significantly larger group then TEK-associated PCG. Future studies using targeted gene deletion or therapies that inhibit PTPRB such as siRNA, antibodies or small molecule inhibitors will provide additional insights and pave the way for translation of these findings into the clinic.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Resource                          Designation                                             Source or reference                        Identifiers                   Additional\
                                                                                                                                                                     information
  --------------------------------- ------------------------------------------------------- ------------------------------------------ ----------------------------- ----------------------------------------------------
  Genetic Reagent (*M. musculus*)   *Ptprb*^NLS-LacZ^                                       [@bib3]                                                                  Maintained on a\
                                                                                                                                                                     mixed background

  Genetic Reagent (*M. musculus*)   *Tek*^+/-^                                              [@bib37]                                   Tek^tm1.1Vlcg^; MGI:5544795   Maintained on a mixed background

  Antibody                          anti-PTPRB (Rabbit polyclonal)                          [@bib26]                                                                 Western blot: 1:2000

  Antibody                          Anti-TEK (Rabbit polyclonal)                            Santa Cruz Biotech                         sc-324                        Western blot 1:2500

  Antibody                          anti-αTubulin (Mouse monoclonal)                        Santa Cruz Biotech                         sc-32293                      Western blot: 1:10,000

  Antibody                          4G10 Platinum anti-phosphotyrosine (Mouse monoclonal)   Millipore                                  05--1050                      Western blot: 1:2000

  Antibody                          anti-CD31 MEC13.3 (Rat monoclonal)                      BD Biosciences                             55337                         IF: 1:100

  Antibody                          anti-PROX1 (Goat polyclonal)                            R and D Systems                            AF2727                        IF: 1:200

  Antibody                          anti-Ki-67 (Rabbit monoclonal)                          ThermoFisher                               MA5-14520                     IF: 1:200

  Antibody                          anti-BRN3b (Goat polyclonal)                            Santa Cruz Biotech                         sc-6026                       IF: 1:1000

  Software,\                        ImageJ Fiji                                             [@bib31]                                   Version 1.52 p                Used for all\
  algorithm                                                                                                                                                          image analysis

  Software, algorithm               Graphpad Prism                                          [Graphpad.com](https://www.graphpad.com)   Version 5.0                   Used for statistical analysis and graph generation

  Software,\                        Adobe Indesign                                          [Adobe.com](https://www.adobe.com/)        Version 14.01 × 64            Used for figure creation
  algorithm                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study approval {#s4-1}
--------------

This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARVO guidelines for care and use of vertebrate research subjects in eye research. All animal experiments were approved by the Animal Care Committee at the Center for Comparative Medicine of Northwestern University (Evanston, Illinois, USA).

Generation and breeding of *Tek^+/-^;Ptprb^NLS-LacZ/WT^*mice {#s4-2}
------------------------------------------------------------

*Ptprb*^NLS-LacZ/WT^ mice have been previously described ([@bib42]; [@bib3]) and were a generous gift of Dr. Dietmar Vestweber (Max Planck Institute, Münster, Germany). *Tek^+/-^* mice were generated by crossing *Tek*^COIN^ ([@bib36]; [@bib11]) mice with *Rosa26^rtTA^;*TetOnCre ([@bib5]) as previously described ([@bib33]). After undergoing Cre-mediated gene deletion, animals were crossed with WT ICR mice to obtain *Tek*^+/-^ animals which did not express the TetOnCre or *Rosa26*^rtTA^ transgenes. Throughout the present study, animals were maintained on a mixed genetic background free of the retina degeneration mutations RD1 and RD8 and allowed unrestricted access to standard rodent chow (Harlan Teklad \#7912; Envigo, Indianapolis IN) and water. As animals were maintained on a mixed background, littermate controls were used for all experiments and animals were included in the study on the basis of full litters (i.e. a control from one litter would not be included without their matching mutant littermates). To determine experimental group sizes, data from our previous studies of SC morphology ([@bib33]; [@bib37]) were used to estimate required numbers. Breeding cages were then set up based on these estimates, and all resulting animals were included in the described studies.

Western blot {#s4-3}
------------

Lung samples from Tek^+/-^, *Ptprb*^NLS-LacZ/WT^ and Tek^+/-^, *Ptprb*^NLS-LacZ/WT^ mice with control littermates were homogenized in RIPA buffer (50 mM TRIS, 150 mM NaCl, 1% IGEPAL CA-630, 0.5% Na Deoxycholate, 0.1% SDS, pH 7.5) containing protease and phosphatase inhibitor cocktails (Sigma). Samples were lysed (30 min at 4°C) and centrifuged (10 min at 14,000\*g, 4°C) before the supernatant was used for western blot and immunoprecipitation. For western blot, 100 μg lysate was separated on a 4--15% Tris-glycine gel (Bio-Rad) and transferred to PVDF membranes using standard methods. Membranes were then cut horizontally at 75 kDa and blocked in (5% BSA in Tris buffered saline containing 0.05% Tween-20, pH 7.5) before incubating with appropriate primary and HRP-conjugated secondary antibodies (Jackson Immunoresearch). After washing, membranes were incubated in ECL substrate (SuperSignal West Pico PLUS, Thermo Fisher) and imaged on an iBright 1500 digital camera system (Thermo Fisher-Life Technologies). Quantification was performed using ImageJ Fiji software ([@bib31]). Values obtained from quantifying total TEK or PTPRB were normalized to matching alpha-tubulin bands obtained from the lower (\<75 kDA) region of the same membrane. Primary antibodies used: Rabbit anti-TEK (Santa Cruz Biotech \#sc-324, 1:2500), mouse anti-alpha tubulin (Santa Cruz Biotech \#sc-32293, 1:10,000), rabbit anti-PTPRB ([@bib26]).

For Immunoprecipitation assays of TEK phosphorylation, 1 mg of protein lysate was incubated with 1 μg rabbit anti-TEK antibody (C-20, Santa Cruz) before antibody-protein complexes were captured using Protein-A conjugated Dynabeads (Invitrogen). Proteins were then eluted by boiling in 2x Laemmli sample buffer containing 100 mM DTT, loaded on a 4--15% Tris-glycine gel and separated by SDS-PAGE as described above. Phosphorylated tyrosine was detected using mouse anti-phospho-tyrosine antibody (4G10 Platinum, Millipore \#05--1050, 1:2000) before membranes were stripped using a commercial stripping solution (Restore, Thermo Fisher \# 21059) and re-probed using anti-TEK antibody as described above. Bands were imaged using a ChemiDock imaging system (Bio-Rad) and quantified as above. Relative TEK phosphorylation is reported in the manuscript as a normalized ratio of pTyr:Total TEK signals obtained from the same membrane. All western blot and immunoprecipitation experiments were performed at least twice. Values and statistics reported are derived from the data shown in the manuscript.

Schlemm's canal immunostaining and imaging {#s4-4}
------------------------------------------

Whole-mount imaging of SC was performed as described previously ([@bib37]; [@bib38]). Briefly, enucleated eye globes were immersion fixed (2% formaldehyde in 0.1M phosphate buffer pH 7.5, 12 hr at 4°C) before the lens and retina were removed and limbal flat mounts were prepared. Tissues were blocked (5% donkey serum, 2.5% bovine serum albumin in Tris buffered saline pH 7.5 containing 0.5% Triton X-100, overnight at 4°C) before incubating in appropriate primary and alexafluor-labled secondary antibodies (Thermo Fisher Scientific, Waltham, MA) diluted in additional blocking buffer. Antibodies used: Rat anti-mouse CD31 (Dilution 1:100. \#55337, BD Biosciences, Franklin Lakes New Jersey), Rabbit anti-human Ki-67 (Dilution 1:200. \#MA5-14520, ThermoFisher Scientific, Waltham, MA), goat anti-human PROX1 (Dilution 1:200. \#AF2727, R and D Systems, Minneapolis, MN). After staining, tissues were washed (Tris buffered saline pH 7.5 containing 0.05% Tween-20) and mounted on microscope slides. Images were captured using a Nikon A1R confocal microscope at the Center for Advanced Microscopy at Northwestern University equipped with a 20x objective with a numerical aperture of 0.75. To measure SC area, 3 10-image Z stacks were captured using a step size of 1.67 μm and a pinhole of 1.2 Airy units at intervals around the circumference of SC. To prevent bias in image location selection, the episclaral vein was used as a landmark for the initial field and subsequent images were taken at 120° intervals. In the manuscript, images of SC are shown as maximum intensity projections of these 10-image Z stacks. Canal area was measured in each 65,536 μm^2^ field using Fiji software ([@bib31]) and an average value was obtained for each eye. Likewise, quantification of Ki-67 and PROX1 expression was performed in three imaging zones from each eye and the results were averaged to obtain the reported value for the animal. eight image confocal Z stacks were obtained with a step size of 1 μm and pinhole of 1.2. Ki-67 positive nuclei were counted manually using ImageJ Fiji software. PROX1 expression was reported as mean background-subtracted fluorescence per μm^2^ CD31+ SC area as measured using ImageJ Fiji software. Quantification of convolutions and focal defects was performed from stitched images of the full SC circumference obtained using the objective described above with the pinhole set to 150 μm.

Intraocular pressure measurement {#s4-5}
--------------------------------

IOP measurements were obtained from awake mice using a Tonolab rebound tonometer (iCare) as previously described ([@bib36]; [@bib15]). Animals were restrained in a soft plastic cone, and average IOPs were recorded from 3 sets of 6 recordings performed by a blinded technician. Finding no difference between left and right eyes, we have reported all IOP measurements as single averaged values for each animal.

Retinal ganglion cell quantification {#s4-6}
------------------------------------

Enucleated eyes from *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice with littermate *Tek*^+/-^, *Ptprb*^NLS-LacZ/WT^, and WT controls were collected at 19 weeks and fixed as above. Retinas were collected before blocking and staining as above. Antibodies used: Goat anti BRN3 (Dilution: 1:1000. Santa Cruz Biotechnology, sc-6026). Retinas were imaged in a standardized pattern as flat mounts using a Nikon A1R microscope as described above and BRN3+ ganglion cells were quantified by a blinded student.

Statistical analysis {#s4-7}
--------------------

Statistical analysis was performed using Prism 5.0 software (Graphpad, La Jolla CA USA). Two-tailed Student's t-test or ANOVA followed by use of Bonferroni's method for multiple comparisons were used for statistical significance testing as appropriate. Throughout the text, values are reported as means ± standard error (SEM). In figures, plotted data points represent average values from individual animals with horizontal lines indicating the group mean. p-values\<0.05 were considered significant and are indicated in figures using the following notation: \*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001.
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Decision letter

Smith

Lois

Reviewing Editor

Boston Children\'s Hospital, Harvard Medical School

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Targeting the phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors present the clinical significance of their work up-front: glaucoma is a major cause of blindness worldwide and elevated intraocular pressure (IOP) from decreased aqueous humor outflow via inadequate Schlemm\'s canal (SC) integrity is a major risk factor for this event. Thomson et al. simply and elegantly demonstrate that haploinsufficiency of VEPTP results in upregulation of Tie2 signaling in vivo and rescues SC agenesis resulting from Tie2 haploinsufficiency. They further demonstrate that compound heterozygosity of VEPTP/*Tek* rescues elevated the IOP and retinal ganglion cell loss observed in *Tek^+/-^* mice. The authors acknowledge the extensive prior work performed by their group and others in this area. The current work adds to this literature by confirming the gene dosage effect of *Tek* and *Ptprb* in maintenance of Schlemm\'s canal and supports the further development of VEPTP inhibitors in the treatment of elevated IOP. The experimental approach is straightforward and logical. Figures are easy to interpret, and the conclusions are well-supported.

Essential revisions:

1\) Introduction/Discussion: Clearly state that studied phenotypes are developmental rather than acquired. Alternatively, consider adding IOP studies with VE-PTP inhibitor in the *Tek^+/-^* mouse.

2\) Figure 1: Include pTyr signaling in the *Ptprb;Tek* compound heterozygotes. Normalization of pTyr relative to *Tek^+/-^* alone would support the conclusion that upregulation of Tie2 signaling is the mechanism of SC/IOP rescue. This could be demonstrated in the eye by western and/or staining.

3\) Figure 2: it would be useful to perform *Tek*, pTek, Prox1, and possibly Ki67 staining in the SC whole mounts, as the authors have done in previous studies. This would support the conclusion that the relative decrease in SC area is associated with defects in *Tek* signaling and subsequent Prox1 activation, as would be expected by the current model of SC development and maintenance. Given the \~two-fold variability in SC area across genotypes, a quantitative correlation may emerge. Short of this, the variability should be discussed.

4\) The authors should show the retinal vascular phenotypes of the *Tek^+/-^, Ptprb*^NLS-LacZ/WT^ and compound *Tek^+/-^;Ptprb*^NLS-LacZ/WT^ mice in Figure 2.

5\) Figure 3: Is there a retinal vascular phenotype in the *Ptprb^+/-^, Tek^+/-^* and compound heterozygote models? This could influence retinal ganglion cell counts.

6\) The authors should make it clear to the readers that the model they use is a constitutive deletion, thus they describe developmental models rather than conditional gene deletion models. The latter would better mimic a therapeutic model.
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Author response

> Essential revisions:
>
> 1\) Introduction/Discussion: Clearly state that studied phenotypes are developmental rather than acquired. Alternatively, consider adding IOP studies with VE-PTP inhibitor in the Tek^+/-^ mouse.

Thank you for pointing out where our Discussion was unclear. We have emphasized this important point in the revised manuscript:

Abstract: "Here, we describe a novel approach to enhance canal formation in these animals by deleting a single allele of the gene encoding the phosphatase PTPRB during development."

Introduction: "Here, we show that developmental deletion of a single *Ptprb* allele..."

Results: "Developmental deletion of a single *Ptprb* allele in *Tek^+/-^;Ptprb*^NLS-LacZ/WT^ mice..."

Discussion: "These defects were blunted by developmental *Ptprb* haploinsufficiency in *Tek*^+/-^;*Ptprb*^NLS-LacZ/WT^ mice..."

> 2\) Figure 1: Include pTyr signaling in the Ptprb;Tek compound heterozygotes. Normalization of pTyr relative to Tek^+/-^ alone would support the conclusion that upregulation of Tie2 signaling is the mechanism of SC/IOP rescue. This could be demonstrated in the eye by western and/or staining.

We have attempted to quantify levels of *Tek* phosphorylation in Schlemm's canal endothelium of haploinsufficient mice, but the low levels of total *Tek* in these animals has made it difficult to obtain convincing results. Quantification of immunostaining using phospho-TEK antibodies showed high variability, making it difficult to draw meaningful conclusions. Western blot of eye and lung tissue was similarly complicated by the lower overall level of TEK expression in haploinsufficient animals.

In light of this difficulty, we have expanded our Discussion to emphasize that while TEK is the most likely substrate, other targets of PTPRB may be implicated in its role in Schlemm's canal.

> 3\) Figure 2: it would be useful to perform Tek, pTek, Prox1, and possibly Ki67 staining in the SC whole mounts, as the authors have done in previous studies. This would support the conclusion that the relative decrease in SC area is associated with defects in Tek signaling and subsequent Prox1 activation, as would be expected by the current model of SC development and maintenance. Given the \~two-fold variability in SC area across genotypes, a quantitative correlation may emerge. Short of this, the variability should be discussed.

We thank the reviewers for these useful suggestions. We have performed whole mount staining of SC at P5 (during canal development) and at P20 (after development is largely complete). These experiments revealed reduced proliferation of PROX1-positive SC endothelial cells (Ki67/PROX1 double positive cells) in *Tek* haploinsufficient mice compared to control littermates at P5, possibly explaining the smaller Schlemm's canal observed in these animals. In contrast, *Ptprb/Tek* double heterozygous animals exhibited a normal proportion of Ki67 positive cells, consistent with their increased SC area. This new data has been included in the manuscript as Figure 2B. Likewise, and consistent with previous work from our lab and other groups (Kim et al., 2017), PROX1 expression is reduced in SC of *Tek*^+/-^ eyes. This reduced PROX1 expression is absent in *Ptprb/Tek* double heterozygous animals, which have normal expression. This data has been included in the manuscript as new Figure 2D.

The reviewers raised an important point regarding the variability in SC area, especially as seen in *Ptprb/Tek* double heterozygous animals. We have previously reported that *Tek^+/-^* mice exhibit a dramatic increase in Schlemm's canal focal malformations, convolutions and narrowings compared to littermate controls. To address the reviewer's question, we now include data which clearly shows that while Schlemm's canal area is substantially larger in *Ptprb/Tek* double heterozygous animals when compared to *Tek^+/-^* littermates, this overall morphological phenotype remains---suggesting that ANGPT-TEK signaling may have a guiding role in canal development which is not recapitulated by nonspecific receptor activation. We have included this data in the manuscript as a new Figure 2E.

> 4\) The authors should show the retinal vascular phenotypes of the Tek^+/-^, Ptprb^NLS-LacZ/WT^ and compound Tek^+/-^;Ptprb^NLS-LacZ/WT^ mice in Figure 2.

We thank the reviewer for raising this important point. We have examined retinal vasculature in littermate mice of all genotypes at P5 (during retinal angiogenesis) and at P20 (after the vascular front has reached the retinal periphery) and found no difference in retinal vascularization. By P20, normal patterning was observed in all three vascular layers and hyaloid vessels were absent in all animals. These new data has been included in the revised manuscript as Figure 3---figure supplement 1.

> 5\) Figure 3: Is there a retinal vascular phenotype in the Ptprb^+/-^, Tek^+/-^ and compound heterozygote models? This could influence retinal ganglion cell counts.

Please see our response to question \#4 (above). Retinal vasculature appeared normal in all animals examined and we have included these data in the revised manuscript.

> 6\) The authors should make it clear to the readers that the model they use is a constitutive deletion, thus they describe developmental models rather than conditional gene deletion models. The latter would better mimic a therapeutic model.

This is a key point in our manuscript, and we appreciate the feedback that it should be clearer. We have emphasized this point in the revised paper as described in our response to point 1 (above).

[^1]: Division of Nephrology, Duke University School of Medicine, Durham, United States.
